EVFM
Evofem Biosciences, Inc. [EVFM] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
EVFM Stock Summary
In the News
EVFM Financial details
Company Rating
-
Market Cap
3.24M
Income
46.76M
Revenue
13.56M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
35
Optionable
No
Shortable
Yes
Earnings
02 Aug 2023
P/E
-0.04
Forward P/E
-
PEG
0
P/S
0.67
P/B
-0.04
P/C
-
P/FCF
-0.16
Quick Ratio
0.04
Current Ratio
0.14
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.24
EPS next Y
-
EPS next Q
-
EPS this Y
-94.4%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
107.97%
EPS Q/Q
-382.5%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-305%
ROE
62%
ROC
-0.25%
Gross Margin
74%
Oper. Margin
101%
Profit Margin
-456%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.012-4.375
52W High
-
52W Low
-
RSI
46.67
Rel Volume
1.77
Avg Volume
844.47K
Volume
1.49M
Perf Week
0%
Perf Month
-16.06%
Perf Quarter
-7.07%
Perf Half Y
-5.15%
-
-
-
-
Beta
-1.23751
-
-
Volatility
0%, 0%
Prev Close
2.22%
Price
0.0092
Change
-3.16%
Company Profile
- Volume Average 844.47K
- Market Capitalization 3.24M
- Employee 35
- CEO Ms. Saundra Pelletier
- Headquarters San Diego,CA,US
- IPO Date 2014-11-20
-
Website
https://www.evofem.com 
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofem Biosciences, Inc. is headquartered in San Diego, California.
